At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CING CINGULATE INC.
Trading 12-23 14:10:50 EST
4.72
+0.62
+15.00%
High4.97
Low4.16
Vol227.91K
Open4.19
D1 Closing4.10
Amplitude19.87%
Mkt Cap15.15M
Tradable Cap15.10M
Total Shares3.21M
T/O1.06M
T/O Rate7.12%
Tradable Shares3.20M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Cingulate's Shares Rise After $5 Million Capital Raise
Press Release: Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market
Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.